Status:
COMPLETED
Dose Escalation Using Fiducial Markers in Image Guided Volumetric Modulated Arc Therapy to the Focal Lesion Micro Boost of Localized Prostate Cancer
Lead Sponsor:
Kasr El Aini Hospital
Conditions:
Prostatic Adenocarcinoma
Eligibility:
All Genders
40-80 years
Phase:
PHASE2
Brief Summary
Gold markers implanted in the prostate are used frequently for position verification of the prostate during external-beam radiotherapy. By using the markers as a surrogate for the prostate itself, not...
Detailed Description
Thirty consecuative loclized prostate cancer patients will be recruited according to inclusion \& exclusion criteria. Once the patient meets the selection criteria stratification will be done accordin...
Eligibility Criteria
Inclusion
- Performance status ECOG: 0-2
- Pathologically proven prostatic adenocarcinoma.
- Localized prostate cancer (Gleason's score: 2-10, Baseline serum prostatic antigen: \>4 ng/dl, T1a-T3b).
- No extra prostatic invading adjacent structures.
- Adequate hematological, renal \& hepatic profile.
- Insertion of more than one fiducial marker in the prostate.
- Patient did verbal \& written consent and adherence to treatment.
Exclusion
- Patient weight \>130 kg.
- Performance status EGOG: 3-4.
- Distant metastasis.
- Previous pelvic radiotherapy.
- Previous prostatectomy.
- Urinary bladder stones.
- General contraindications for MRI (i.e. cardiac pacemaker, metal implants or history of severe allergic reaction after administration of contrast agent).
- Concomitant neoplastic disease or previous anti neoplastic therapy.
Key Trial Info
Start Date :
May 1 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2018
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT03384199
Start Date
May 1 2016
End Date
April 1 2018
Last Update
August 14 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Radwa Fawzy Saleh Ahmed
Cairo, Maadi, Egypt, 11728